We are live on ! Find out more
CNST

Constellation Pharmaceuticals, Inc.
CNST

Delisted

CNST was delisted on the 14th of July, 2021.

Back to rankings

44 hedge funds and large institutions have $225M invested in Constellation Pharmaceuticals, Inc. in 2019 Q1 according to their latest regulatory filings, with 11 funds opening new positions, 17 increasing their positions, 7 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

264% more capital invested

Capital invested by funds: $61.9M → $225M (+$163M)

175% more first-time investments, than exits

New positions opened: 11 | Existing positions closed: 4

143% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 7

19% more funds holding

Funds holding: 37 → 44 (+7)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

Holders
44
Holders Change
+7
Holders Change %
+18.92%
% of All Funds
0.95%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
11
Increased
17
Reduced
7
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$5.56M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$3.1M
3
State Street
State Street
Massachusetts
+$1.44M
4
Northern Trust
Northern Trust
Illinois
+$706K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$680K

Top Sellers

Rank Fund Capital Flow
1
DM
Deerfield Management
New York
-$3.43M
2
EC
EcoR1 Capital
California
-$318K
3
SFM
Sphera Funds Management
Israel
-$269K
4
Jacobs Levy Equity Management
Jacobs Levy Equity Management
New Jersey
-$108K
5
Morgan Stanley
Morgan Stanley
New York
-$57.8K
Name Holding Trade Value Shares
Change 		Change in
Stake
PS
1
Peter Svennilson
$63.4M +$9 +1 +0%
TG
2
TRV GP
Massachusetts
$41.1M – – –
Fidelity Investments
3
Fidelity Investments
Massachusetts
$21.3M -$1.79K -200 -0%
CC
4
Casdin Capital
New York
$21.1M +$9 +1 +0%
CAM
5
Cormorant Asset Management
Massachusetts
$17.2M – – –
O
6
OrbiMed
New York
$11.3M – – –
VMI
7
VHCP Management II
New York
$9.85M – – –
BlackRock
8
BlackRock
New York
$9.84M +$5.56M +619,868 +582%
Vanguard Group
9
Vanguard Group
Pennsylvania
$5.5M +$3.1M +345,913 +578%
HIM
10
Hillhouse Investment Management
Cayman Islands
$4.31M – – –
DM
11
Deerfield Management
New York
$3.43M -$3.43M -382,443 -60%
State Street
12
State Street
Massachusetts
$2.41M +$1.44M +161,156 +954%
BBA
13
Baker Bros. Advisors
New York
$1.81M – – –
Northern Trust
14
Northern Trust
Illinois
$1.76M +$706K +78,802 +154%
First Eagle Investment Management
15
First Eagle Investment Management
New York
$1.69M – – –
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.21M +$680K +75,852 +552%
VMI
17
VHCP Management III
New York
$903K – – –
EIM
18
Essex Investment Management
Massachusetts
$897K +$593K +66,186 New
JRP
19
Jasper Ridge Partners
California
$835K -$9 -1 -0%
Canada Pension Plan Investment Board
20
Canada Pension Plan Investment Board
Ontario, Canada
$678K +$448K +50,000 New
SFM
21
Sphera Funds Management
Israel
$544K -$269K -30,000 -43%
Bank of New York Mellon
22
Bank of New York Mellon
New York
$517K +$342K +38,210 New
PCM
23
Prelude Capital Management
New York
$454K +$301K +33,538 New
Charles Schwab
24
Charles Schwab
California
$438K +$290K +32,312 New
BCM
25
Bridgeway Capital Management
Texas
$373K +$246K +27,500 New
1
2

CNST Hedge Fund Activity: Q1 2019 in Review

44 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in Constellation Pharmaceuticals, Inc. (CNST) for Q1 2019, worth a combined $225M — up 264% from $61.9M a quarter earlier.

Buyers outnumbered sellers: 11 funds opened new CNST positions and 4 closed out — a net gain of 7 holders — while 17 added to existing stakes and 7 trimmed.

The largest buyer was BlackRock, adding an estimated $5.56M. The largest seller was Deerfield Management, cutting an estimated $3.43M.

  • 44 institutional investors held Constellation Pharmaceuticals, Inc. (CNST) as of Q1 2019, up from 37 in Q4 2018.
  • Funds reported $225M of Constellation Pharmaceuticals, Inc. stock for Q1 2019, up 264% quarter-over-quarter.
  • 11 funds opened new Constellation Pharmaceuticals, Inc. positions in Q1 2019 and 4 closed out, a net change of +7 holders.
  • The largest Constellation Pharmaceuticals, Inc. buyer in Q1 2019 was BlackRock, an estimated $5.56M added.
  • The largest Constellation Pharmaceuticals, Inc. seller in Q1 2019 was Deerfield Management, an estimated $3.43M sold.

Based on aggregated 13F filings for Q1 2019.